Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integrated DNA Technologies Launches its First Cancer Panel

Published: Friday, October 25, 2013
Last Updated: Friday, October 25, 2013
Bookmark and Share
Fast and accurate screening for mutations identified in acute myeloid lymphoma using the xGen® Acute Myeloid Lymphoma Panel v1.0.

Integrated DNA Technologies (IDT) is enabling cancer research with its latest next generation sequencing (NGS) product, the xGen® Acute Myeloid Leukemia Cancer Panel v1.0.

Consisting of 11,743 xGen Lockdown® Probes, this cancer panel targets over 260 clinically relevant genes that were found to be mutated in a study of 200 patients with acute myeloid leukemia (AML), and published by The Cancer Genome Atlas consortium.

The AML Cancer Panel is used for enriching the genome for regions of interest before performing NGS. It can, therefore, be used to study disease occurrence and progression, and help with the development of better targeted therapies.

Target enrichment enables users to focus their sequencing efforts on specific regions of the genome, providing a cost-effective and reliable alternative to whole genome sequencing, making NGS more accessible to researchers.

By including only relevant xGen Lockdown Probes, the AML Cancer Panel enables high coverage of targeted regions, with minimal GC bias.

As cancer is a genetic disease driven by both heritable and somatic mutations, NGS technologies can significantly improve its detection, management, and treatment.

DNA from a patient could be enriched for these AML-related genes using capture panels such as the xGen AML Cancer Panel and sequenced to identify mutated genes. Subsequently, the patient would receive therapy specific to their cancer profile.

Periodic sequencing of these genes would allow monitoring of disease progression for both research and clinical purposes. As such, more tailored therapies can be developed and a personalized treatment regimen can be implemented.

Ibrahim Jivanjee, Product Manager for NGS at IDT, commented, “We have invested a significant amount of resources into the development of our xGen product line, and are delighted to see such success from these products already. The launch of our first cancer panel has been a significant milestone, with early collaborators demonstrating its potential for use in patient diagnosis and monitoring.”

He continued, “With next gen sequencing becoming an increasingly prominent technique within cancer diagnosis and personalized medicine, IDT, with its leading position in oligonucleotide technology will continue to be at the forefront of developments in this rapidly advancing field.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Untangling the Web of Gene Expression
New technology for understanding gene expression drives research forward.
Wednesday, May 20, 2015
Discover Affordable Custom NGS Panels
IDT webinar helps NGS researchers bring cost-savings to target capture panels.
Thursday, February 12, 2015
Synthetic Biology Webinar - Genome Modifications Made Easy
IDT reveals how to overcome the challenges of CRISPR-mediated genome editing.
Thursday, January 15, 2015
Discover the Latest NGS-Based Assays Guiding Precision Oncology
IDT joins forces with Foundation Medicine in AMP workshop.
Saturday, November 08, 2014
IDT Acquires SURVEYOR® Nuclease Business from Transgenomic
Addition of SURVEYOR enzyme and kits expands IDT's molecular biology product offerings.
Wednesday, July 02, 2014
World Cup 2014 - with a Scientific Twist
IDT fuses fruit flies, football and fun in a unique global contest with great prizes.
Thursday, June 12, 2014
Summit Partners Makes Growth Equity Investment in IDT
IDT’s founder, Dr. Joseph Walder, will remain the company’s majority owner.
Wednesday, March 19, 2014
Enhanced Molecular Inversion Probes for NGS Target Enrichment
IDT presents latest developments at 15th annual Advances in Genome Biology and Technology meeting.
Tuesday, February 04, 2014
Providing a Rapid and Reliable Method of Gene Cloning
Integrated DNA Technologies will be speaking at the upcoming Antibody Engineering and Therapeutics conference.
Monday, December 02, 2013
IDT Provides Insights into the World of Gene Construction
Informative and educational talk to take place at SynBioBeta 2013.
Thursday, November 14, 2013
Discussing the Science of Big DNA
Read about the most recent advances in synthetic biology in the latest issue of DECODED.
Monday, September 23, 2013
IDT Opens SGD 6 Million Manufacturing Facility in Singapore
IDT is now able to provide locally-manufactured oligonucleotides to researchers in Singapore and throughout the region.
Wednesday, July 24, 2013
Webinar: the Cutting-edge qPCR Approach to Single-cell Expression Profiling
Join IDT and Professor Mikael Kubista for insight into pioneering qPCR methods, June 25.
Monday, June 24, 2013
Building Novel DNA Constructs at ASM
IDT invite scientists to discover a cost-effect approach to sequence constructs.
Tuesday, May 14, 2013
IDT and SGI-DNA Broaden Their Collaboration
Both Companies expand partnership to provide synthetic DNA products up to 2 Mbp.
Friday, March 01, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!